At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
ATI-50002drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
In Brief
A Phase 2 clinical trial evaluating ATI-50002 for Androgenetic Alopecia. Completed, enrolled 31 participants across 3 sites.
Detailed Summary
Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAndrogenetic Alopecia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartMar 2018
First PostedApr 2018
Primary CompletionOct 2019
Study CompletionOct 2019
TodayJul 2026
First PostedApr 12, 2018
Enrollment StartMar 22, 2018
Primary CompletionOct 15, 2019
Study CompletionOct 30, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.2 years ago
Interventions
ATI-50002drug
ATI-50002 Topical Solution